USA flag logo/image

An Official Website of the United States Government

IMMUNOHISTOCHEMICAL STUDY OF ORAL DYSPLASIA AND CARCINOMA

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
4860
Program Year/Program:
1987 / SBIR
Agency Tracking Number:
4860
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Intek Diagnostics Inc.
1450 Rollins Road Burlingame, CA 94010
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 1987
Title: IMMUNOHISTOCHEMICAL STUDY OF ORAL DYSPLASIA AND CARCINOMA
Agency: HHS
Contract: N/A
Award Amount: $126,000.00
 

Abstract:

THERE ARE NO SENSITIVE IN VITRO DIAGNOSTIC TESTS FOR THE DETECTION OF ORAL DYSPLASIA OR CARCINOMA. ALTHOUGH FRANK MALIGNANCIES ARE MORE READILY DIAGNOSED, THERE ARE INCONSISTENCIES IN THE CATEGORIZING AND DIAGNOSIS OF WHAT ARE GENERALLY TERMED PREMALIGNANT CONDITIONS. IMMUNO- DIAGNOSIS MAY PROVE SUPERIOR TO THE CURRENT METHOD OF SUBJECTIVE EVALUATION OF CELLULAR MORPHOLOGY, NOT ONLY IN TERMS OF SPEED AND SENSITIVITY, BUT ALSO IN OBJECTIVITY. THE DEVELOPMENT OF A COCKTAIL OF HIGHLY ASSOCIATED SQUAMOUS CELL CARCINOMA MONOCLONAL ANTIBODIES TO BE USED AS AN IMMUNOHISTOCHEMICAL REAGENT WILL CONTRIBUTE TO THE EFFECTIVEDIAGNOSIS OF ORAL DISEASE. THE LONG-RANGE GOAL OF THE RESEARCH IS TO PRODUCE AN IMMUNOHISTOCHEMICAL REAGENT WHICH WILL DETECT ALL STAGES OF SQUAMOUS CELL CARCINOMA AS WELL ASALL CELLS WITHIN THE TUMOR MASS AND DETECT PREMALIGNANT LESIONS. THOSE MONOCLONALS SELECTED IN PHASE I WILL BE EVALUATED IN A LARGE-SCALE PHASE II CLINICAL STUDY.

Principal Investigator:

Raymond Ranken
Principal Investigator
4153400530

Business Contact:

Small Business Information at Submission:

Intek Diagnostics Inc.
1450 Rollins Road Burlingame, CA 94010

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No